This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Epoetin delta
- DrugBank Accession Number
- DB11624
- Background
Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
- Type
- Biotech
- Groups
- Approved, Investigational, Withdrawn
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Epoetin delta
- External IDs
- HMR-4396
- HMR4396
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCyclophosphamide The risk or severity of pulmonary toxicity can be increased when Epoetin delta is combined with Cyclophosphamide. Vinblastine The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinblastine. Vincristine The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincristine. Vindesine The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vindesine. Vinflunine The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinflunine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dynepo Injection, solution 5000 IU Intravenous; Subcutaneous Shire Pharmaceutical Contracts Limited 2016-09-07 2009-04-23 EU 
Dynepo Injection, solution 3000 IU Intravenous; Subcutaneous Shire Pharmaceutical Contracts Limited 2016-09-07 2009-04-23 EU Dynepo Injection, solution 8000 IU Intravenous; Subcutaneous Shire Pharmaceutical Contracts Limited 2016-09-07 2009-04-23 EU Dynepo Injection, solution 10000 IU Intravenous; Subcutaneous Shire Pharmaceutical Contracts Limited 2016-09-07 2009-04-23 EU Dynepo Injection, solution 2000 IU Intravenous; Subcutaneous Shire Pharmaceutical Contracts Limited 2016-09-07 2009-04-23 EU
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 474EI5756Y
- CAS number
- 261356-80-3
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Terminated Other Anemia / Renal Failure, Chronic Renal Failure 1 3 Terminated Treatment Anemia / Kidney Failure 1 Not Available Terminated Not Available Anemia / Kidney Diseases / Renal Failure, Chronic Renal Failure 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous; Subcutaneous 1000 IU Injection, solution Intravenous; Subcutaneous 10000 IU Injection, solution Intravenous; Subcutaneous 2000 IU Injection, solution Intravenous; Subcutaneous 3000 IU Injection, solution Intravenous; Subcutaneous 4000 IU Injection, solution Intravenous; Subcutaneous 5000 IU Injection, solution Intravenous; Subcutaneous 6000 IU Injection, solution Intravenous; Subcutaneous 8000 IU - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 17, 2016 20:07 / Updated at February 21, 2021 18:53